92 related articles for article (PubMed ID: 3135514)
1. Effect of food on the serum concentration profile of enteric-coated valproic acid.
Fischer JH; Barr AN; Paloucek FP; Dorociak JV; Spunt AL
Neurology; 1988 Aug; 38(8):1319-22. PubMed ID: 3135514
[TBL] [Abstract][Full Text] [Related]
2. Meal-dependent absorption of enteric-coated sodium valproate.
Levy RH; Cenraud B; Loiseau P; Akbaraly R; Brachet-Liermain A; Guyot M; Gomeni R; Morselli PL
Epilepsia; 1980 Jun; 21(3):273-80. PubMed ID: 6769666
[TBL] [Abstract][Full Text] [Related]
3. Comparative absorption profiles of divalproex sodium delayed-release versus extended-release tablets -- clinical implications.
Dutta S; Reed RC; O'Dea RF
Ann Pharmacother; 2006 Apr; 40(4):619-25. PubMed ID: 16569797
[TBL] [Abstract][Full Text] [Related]
4. Comparative steady state serum levels of valproic acid administered as two different formulations--Deprakine and Orfiril.
Johannessen SI; Henriksen O
Acta Neurol Scand; 1979 Dec; 60(6):371-4. PubMed ID: 121513
[TBL] [Abstract][Full Text] [Related]
5. Effect of delayed and/or missed enteric-coated divalproex doses on valproic acid concentrations: simulation and dose replacement recommendations for the clinician.
Dutta S; Reed RC
J Clin Pharm Ther; 2006 Aug; 31(4):321-9. PubMed ID: 16882100
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effectiveness of several formulations of sodium valproate: tablets, enteric-coated capsules, solutions and rectal capsules.
Battino D; Biraghi M; Cusi C; Nespolo A; Avanzini G
Ital J Neurol Sci; 1982 Oct; 3(3):197-200. PubMed ID: 6819250
[TBL] [Abstract][Full Text] [Related]
7. Once-daily dosing is appropriate for extended-release divalproex over a wide dose range, but not for enteric-coated, delayed-release divalproex: evidence via computer simulations and implications for epilepsy therapy.
Reed RC; Dutta S; Liu W
Epilepsy Res; 2009 Dec; 87(2-3):260-7. PubMed ID: 19892524
[TBL] [Abstract][Full Text] [Related]
8. Distinct absorption characteristics of oral formulations of valproic acid/divalproex available in the United States.
Dutta S; Reed RC
Epilepsy Res; 2007 Mar; 73(3):275-83. PubMed ID: 17208410
[TBL] [Abstract][Full Text] [Related]
9. Every-12-hour administration of extended-release divalproex in patients with epilepsy: impact on plasma valproic acid concentrations.
Reed RC; Dutta S; Cavanaugh JH; Locke C; Granneman GR
Epilepsy Behav; 2006 Mar; 8(2):391-6. PubMed ID: 16473558
[TBL] [Abstract][Full Text] [Related]
10. Single-dose kinetics and bioavailability of sodium-hydrogen divalproate.
Anderson P; Elwin CE
Clin Neuropharmacol; 1985; 8(2):156-64. PubMed ID: 3924399
[TBL] [Abstract][Full Text] [Related]
11. Does it really matter when a blood sample for valproic acid concentration is taken following once-daily administration of divalproex-ER?
Reed RC; Dutta S
Ther Drug Monit; 2006 Jun; 28(3):413-8. PubMed ID: 16778728
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of valproic acid obtained after administration of three oral formulations to humans.
Bialer M; Hussein Z; Dubrovsky J; Raz I; Abramsky O
Isr J Med Sci; 1984 Jan; 20(1):46-9. PubMed ID: 6421770
[TBL] [Abstract][Full Text] [Related]
13. Absolute bioavailability and absorption characteristics of divalproex sodium extended-release tablets in healthy volunteers.
Dutta S; Reed RC; Cavanaugh JH
J Clin Pharmacol; 2004 Jul; 44(7):737-42. PubMed ID: 15199078
[TBL] [Abstract][Full Text] [Related]
14. Absorption characteristics of a new valproate formulation: divalproex sodium-coated particles in capsules (Depakote Sprinkle).
Carrigan PJ; Brinker DR; Cavanaugh JH; Lamm JE; Cloyd JC
J Clin Pharmacol; 1990 Aug; 30(8):743-7. PubMed ID: 2119396
[TBL] [Abstract][Full Text] [Related]
15. Drug-Drug Interaction Studies of Paliperidone and Divalproex Sodium Extended-Release Tablets in Healthy Participants and Patients with Psychiatric Disorders.
Remmerie B; Ariyawansa J; De Meulder M; Coppola D; Berwaerts J
J Clin Pharmacol; 2016 Jun; 56(6):683-92. PubMed ID: 26412032
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of enteric-coated valproic acid.
Albright PS; Bruni J; Suria D
Ther Drug Monit; 1984; 6(1):21-3. PubMed ID: 6424275
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacokinetic study of sodium di-n-propylacetate (usual tablet and enteric coated tablet with delayed absorption) (author's transl)].
van de Mortel I; franck G
Acta Neurol Belg; 1976; 76(3):165-72. PubMed ID: 788439
[TBL] [Abstract][Full Text] [Related]
18. [Seven cases of decreased serum valproic acid concentration during concomitant use of carbapenem antibiotics].
Lee SG; Kim JH; Joo JY; Kwon OH
Korean J Lab Med; 2007 Oct; 27(5):338-43. PubMed ID: 18094598
[TBL] [Abstract][Full Text] [Related]
19. Effect of food on the absorption and pharmacokinetics of prednisolone from enteric-coated tablets.
Al-Habet SM; Rogers HJ
Eur J Clin Pharmacol; 1989; 37(4):423-6. PubMed ID: 2598978
[TBL] [Abstract][Full Text] [Related]
20. Successful initiation of combined therapy with valproate sodium injection and divalproex sodium extended-release tablets in the epilepsy monitoring unit.
Boggs JG; Preis K
Epilepsia; 2005 Jun; 46(6):949-51. PubMed ID: 15946337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
